The demand for GLP-1s isnt just about filling prescriptions
A 2024 FDA investigation of seized GLP-1 peptide samples found that 15% contained bacterial endotoxins exceeding safety limits
Originally developed in the early 1990s by Professor Frank Ng and colleagues at Monash University in Australia, this peptide was engineered to isolate the lipolytic (fat-metabolizing) properties of growth hormone while eliminating its growth-promoting, diabetogenic, and IGF-1-stimulating effects
Despite its efficacy, acitretin is often limited by its side effect profile, including mucocutaneous dryness and hyperlipidemia
The bottom line on semaglutide and blood clots After reviewing every available study, case report, and biological mechanism, here is what we can say with reasonable confidence
Hence, future studies should implement standardized imaging protocols or establish conversion factors to enhance longitudinal comparability